Aim: To evaluate the safety and efficacy of 12 months of zoledronic acid (ZA) administered every 6 months to children with osteoporosis. Methods: Retrospective cohort study of 27 patients (16 male, 11 female) treated with ZA (0.05 mg/kg/dose) every 6 months for 1 year. 20 were immobile, 4 steroid-induced osteoporosis, 2 idiopathic osteoporosis and 1 neurofibromatosis type 1. 16 had long bone fractures and 12 had vertebral wedging at baseline. Mineral homeostasis, bone mineral density (BMD) and vertebral morphometry were evaluated at baseline and 12 months. Results were compared to published data on 3-monthly ZA treatment. Results: Median age at ZA start was 10.5 years (range 6.2-13.3). Following the first infusion, 2 developed asymptomatic hypocalcemic, 14 developed temperature >38°C, 13 aches/pain and 6 nausea. At 12 months, there was reduction in bone turnover and improvement in BMD and vertebral shape. No patient fractured after starting ZA. Growth was normal. Outcomes were similar to 3-monthly ZA. Conclusion: ZA administered 6-monthly was associated with acute phase reaction to the first dose and improvement in BMD, reduction in bone turnover and improved vertebral shape at 12 months.

Keywords:
Zoledronic acid, Osteoporosis, Children, Bisphosphonate
1.
Munns CF, Cowell CT: Prevention and treatment of osteoporosis in chronically ill children. J Musculoskelet Neuronal Interact 2005;5:262-272.
2.
Bachrach LK, Ward LM: Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94:400-409.
3.
Ward L, Tricco A, Phuong PN, et al: Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007;4:CD005324.
4.
Glorieux FH: Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics 2007;119:S163-S165.
5.
Rauch F, Travers R, Plotkin H, et al: The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002;110:1293-1299.
6.
Rauch F, Glorieux FH: Osteogenesis imperfecta. Lancet 2004;363:1377-1385.
7.
Rauch F, Plotkin H, Zeitlin L, et al: Bone mass, size and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003;18:610-614.
8.
Land C, Rauch F, Munns CF, et al: Vertebral morphology in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006;39:901-906.
9.
Fleisch H: Bisphosphonates in Bone Disease: From the Laboratory to the Patient, ed 4. San Diego, Academic Press, 2000.
10.
Brown JJ, Zacharin MR: Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab 2009;22:55-63.
11.
Grey A, Bolland M, Wattie D, et al: Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res 2010;25:2251-2255.
12.
Simm PJ, Johannesen J, Briody J, et al: Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis. Bone 2011;49:939-943.
13.
Baim S, Leonard MB, Bianchi ML, et al: Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 2008;11:6-21.
14.
Kuczmarski RJ, Ogden CL, Guo SS, et al: 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002;246:1-190.
15.
Tanner JM: Growth at Adolescence, ed 2. Oxford, Blackwell Scientific, 1962.
16.
Carter DR, Bouxsein ML, Marcus R: New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992;7:137-145.
17.
Lu PW, Briody JN, Ogle GD, et al: Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994;9:1451-1458.
18.
Ogle GD, Allen JR, Humphries IR, et al: Body-composition assessment by dual-energy x-ray absorptiometry in subjects aged 4-26 years. Am J Clin Nutr 1995;61:746-753.
19.
Högler W, Briody J, Woodhead HJ, et al: Importance of lean mass in the interpretation of total body densitometry in children and adolescents. J Pediatr 2003;143:81-88.
20.
Genant HK, Wu CY, van Kuijk C, et al: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-1148.
21.
Vuorimies I, Toiviainen-Salo S, Hero M, et al: Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr 2011;75:346-353.
22.
Gordon CM, Bachrach LK, Carpenter TO, et al: Duel energy x-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008;11:43-58.
23.
Grissom LE, Harcke HT: Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003;33:226-229.
24.
Rauch F, Travers R, Munns C, et al: Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 2004;19:1191-1193.
25.
Rauch F, Munns C, Land C, et al: Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 2006;91:1268-1274.
26.
Rauch F, Cornibert S, Cheung M, et al: Long-bone changes after pamidronate discontinuation in children adolescents with osteogenesis imperfecta. Bone 2007;40:821-827.
27.
Simmons JH, Zeitler PS: Osteopenia in pediatric patients: when and how to intervene. Curr Opin Endocrinol Diabetes 2006;13:21-25.
28.
Marini JC: Bone: Use of bisphosphonates in children-proceed with caution. Nat Rev Endocrinol 2009;5:241-243.
29.
Whyte MP, Wenkert D, Clements KL, et al: Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-463.
30.
Brown JJ, Ramalingam L, Zacharin MR: Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol 2008;68:863-867.
31.
Munns CF, Rauch F, Ward L, et al: Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004;19:1742-1745.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.